Ardent Health vs Tenet Healthcare
ARDT and THC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARDT and THC compare
Tenet Healthcare is the larger company, worth 9.1 times as much as Ardent Health ($22.8B against $2.5B).
On earnings, Tenet Healthcare is cheaper: it trades at 8.3× trailing earnings, against 17.3× for Ardent Health.
Tenet Healthcare grew revenue faster over the last twelve months (6.2% versus 2.0% for Ardent Health).
Tenet Healthcare scores higher on the StockData Score (13 against 9 for Ardent Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARDT | THC |
|---|---|---|
| Size and price | ||
| Market cap | $2.5B | $22.8B |
| Share price | $17.80 | $286.03 |
| Change, 1 year | 26.7% | 43.0% |
| Change, 5 years | – | 269% |
| Beta (5Y) | 0.31 | 1.13 |
| Employees | 25K | 100K |
| StockData Score | ||
| Total score | 9 | 13 (better) |
| Valuation score | 4 | 5 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.3× | 8.3× (better) |
| P/S | 0.4× (better) | 1.0× |
| P/B | 1.8× (better) | 4.2× |
| EV/EBITDA | 7.1× | 5.6× (better) |
| P/FCF | – | 6.8× |
| PEG | – | 0.14 |
| FCF yield | – | 14.6% |
| Fair value | $23.31 | $456.45 |
| Margin of safety | 23.6% | 37.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 2.0% | 6.2% (better) |
| Revenue growth, 5Y average | – | 3.9% |
| Net income growth (TTM) | −28.7% | – |
| EPS growth (TTM) | −29.0% | 136% (better) |
| EPS growth, 5Y average | – | 32.8% |
| Profitability | ||
| Operating margin | – | 24.4% |
| Net margin | 2.3% | – |
| FCF margin | – | 15.0% |
| Return on equity | 11.1% | – |
| Return on invested capital | – | 28.2% |
| Financial health | ||
| Debt / equity | 0.79 (better) | 2.43 |
| Net debt / EBITDA | 0.73 (better) | 1.68 |
| Interest coverage | – | 6.6× |
| Current ratio | 2.13 (better) | 1.58 |
| Altman Z-score | 2.04 | 2.31 (better) |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Buyback yield | – | 8.0% |
| Shareholder yield | 0.00% | 8.0% (better) |
| Ownership | ||
| Held by institutions | 76.9% | 101% |
| Held by insiders | 78.9% | 0.97% |
| Insider net buying, 12 months | $186K (better) | −$62.9M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 11.6% | 2.3% |
Go deeper
- ARDT stock overview
- ARDT income statement
- ARDT valuation and score
- THC stock overview
- THC income statement
- THC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.